Alantolactone CAS: 546-43-0

CAS NO: 546-43-0
Alantolactone
Chemical Name: Alantolactone
Molecular Formula: C15H20O2
Formula Weight: 232.32
CAS No.: 546-43-0
Description Review
Description

Alantolactone is a naturally occurring sesquiterpene lactone found in various plants, including Inula helenium and Radix bupleuri. It has gained attention for its potential therapeutic properties in various diseases, including inflammation, cancer, and microbial infections. Alantolactone targets several signaling pathways involved in these diseases, making it a promising candidate for the development of novel therapeutics.

Chemical name:

(4aS,6aR,8aS)-3a,4,4a,5,6,6a,7,8,9,10-decahydro-8a-hydroxy-4a,8-dimethyl-2-oxo-1H-naphthalen-1-yl acrylate

Molecular formula:

C15H20O3

Formula weight:

248.32 g/mol

CAS No:

546-43-0

Top ten keywords from Google and Synonyms:

  1. Alantolactone
  2. Sesquiterpene lactone
  3. Inflammation
  4. Cancer
  5. Microbial infections
  6. Signaling pathways
  7. NF-kB
  8. MAPKs
  9. Apoptosis
  10. Antimicrobial

Health benefits of this product:

Alantolactone has shown potential health benefits in the treatment of various diseases, including inflammation, cancer, and microbial infections. Studies have shown that alantolactone can inhibit the production of pro-inflammatory cytokines, reduce oxidative stress, induce apoptosis in cancer cells, and exhibit antimicrobial activity. Additionally, alantolactone has been found to have neuroprotective effects, protecting against neuronal damage and reducing inflammation in the brain.

Potential effects:

Alantolactone has several potential effects on the body. One of the primary mechanisms is through the inhibition of several signaling pathways involved in inflammation, oxidative stress, and cancer cell proliferation, including NF-kB and MAPKs. By inhibiting these pathways, alantolactone can reduce oxidative stress and inflammation, induce apoptotic cell death in cancer cells, and exhibit antimicrobial activity. Additionally, alantolactone has been found to have neuroprotective effects, protecting against neuronal damage and reducing inflammation in the brain.

Product mechanism:

Alantolactone works by targeting several signaling pathways involved in inflammation, oxidative stress, and cancer cell proliferation. One of the primary mechanisms is through the inhibition of NF-kB and MAPKs, which play key roles in cellular responses to stress and inflammation. By inhibiting these pathways, alantolactone can reduce oxidative stress and inflammation, induce apoptotic cell death in cancer cells, and exhibit antimicrobial activity. Additionally, alantolactone has been found to have neuroprotective effects, protecting against neuronal damage and reducing inflammation in the brain.

Safety:

Alantolactone has been found to be generally safe in preclinical studies. However, further research is needed to determine the safety and efficacy of alantolactone in humans.

Side effects:

Currently, there is limited information available regarding the potential side effects of alantolactone. Some studies have reported mild adverse events such as nausea and gastrointestinal disturbances. Further research is needed to determine the full extent of the drug's side effects.

Dosing information:

There are currently no established guidelines for the dosing of alantolactone in humans. Doses used in preclinical studies have ranged from 0.1 to 100 mg/kg. Further research is needed to determine the optimal dosing regimen for alantolactone in humans.

Conclusion:

Alantolactone is a naturally occurring compound with potential therapeutic properties in the treatment of various diseases, including inflammation, cancer, and microbial infections. The drug has been shown to target several signaling pathways involved in these diseases, making it a promising candidate for the development of novel therapeutics. However, its safety and efficacy in humans need to be further studied. Overall, alantolactone shows great promise as a targeted therapy for various diseases, and may provide valuable insights into the development of future treatments for inflammatory, neoplastic, and infectious disorders

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code